What Is Retatrutide? The Triple-Agonist Changing Weight Loss in 2026

If you have been following medical weight loss, you know the names: semaglutide, tirzepatide, Ozempic, Wegovy, Mounjaro, Zepbound. These medications have produced results that were genuinely unthinkable a decade ago — 15 to 22 percent body weight loss from a once-weekly injection, without bariatric surgery and without extreme calorie restriction.

But there is a newer compound generating even more excitement among researchers and clinicians — retatrutide. It targets three metabolic pathways instead of one or two, and early clinical data suggests it may produce the most dramatic weight loss results of any pharmaceutical intervention ever studied.

This article explains exactly what retatrutide is, how it works, what the data actually shows, and why most Miami clinics are not yet offering it.

How Retatrutide Works: The Triple-Agonist Advantage

To understand why retatrutide produces larger weight loss results than its predecessors, you need to understand the three metabolic pathways it activates simultaneously.

GLP-1 Agonism — The Appetite Pathway

GLP-1 (glucagon-like peptide-1) is the incretin hormone that semaglutide targets. When you activate GLP-1 receptors, several things happen: appetite is suppressed through signaling in the hypothalamus and brainstem, gastric emptying slows, insulin release becomes more glucose-responsive, and inappropriate glucagon release after meals is reduced. The result is less hunger, smaller portions, and better blood sugar regulation.

This is the core mechanism behind every GLP-1 medication on the market. It works — semaglutide produced approximately 14.9 percent body weight loss in the STEP 1 trial. But it works primarily by reducing caloric intake.

GIP Agonism — The Metabolic Efficiency Pathway

GIP (glucose-dependent insulinotropic polypeptide) is a second incretin hormone that tirzepatide adds to the GLP-1 pathway. GIP enhances insulin sensitivity, influences how fat is stored and metabolized in adipose tissue, and works synergistically with GLP-1 to amplify appetite suppression.

Adding GIP to GLP-1 is what allowed tirzepatide to outperform semaglutide in head-to-head trials, producing approximately 22.5 percent weight loss in the SURMOUNT-1 trial compared to semaglutide’s 14.9 percent. Two pathways are better than one.

Glucagon Agonism — The Energy Expenditure Pathway

The glucagon pathway is where retatrutide separates itself from every other weight loss medication currently available or in late-stage development.

Glucagon is a hormone produced by the alpha cells of the pancreas. Its conventional role is to raise blood sugar when levels drop too low, but it has another effect that is critical for weight management: it increases energy expenditure. Specifically, glucagon receptor activation raises resting metabolic rate, promotes fat oxidation in the liver (beta-oxidation), and stimulates thermogenesis in brown adipose tissue.

A landmark study published in The Journal of Clinical Investigation demonstrated that glucagon infusion increases energy expenditure by 100 to 200 calories per day in humans (1). That may sound modest, but compounded daily over months of treatment, it represents substantially more fat loss than appetite suppression alone.

Why Three Pathways Outperform Two

Semaglutide reduces the input side of the energy balance equation. Tirzepatide reduces input more efficiently. Retatrutide reduces input and increases output. The simplest way to think about it: semaglutide and tirzepatide help you eat less. Retatrutide helps you eat less and burn more.

That is why retatrutide can produce weight loss results that exceed what dual-agonists achieve, even in shorter trial durations.

The Clinical Data

Phase 2 Trial Results (Jastreboff et al., NEJM 2023)

The landmark Phase 2 trial of retatrutide enrolled 338 adults with obesity or overweight with a weight-related condition. Participants were randomized to retatrutide at 1, 4, 8, or 12 mg weekly or to placebo for 48 weeks (2). The results:

• 12 mg dose: Average weight loss of 24.2 percent of body weight
• 8 mg dose: Average weight loss of 22.8 percent
• 4 mg dose: Average weight loss of 17.0 percent
• Placebo: Average weight loss of 2.1 percent

More than 90 percent of participants receiving the 8 or 12 mg dose lost at least 10 percent of body weight. More than 75 percent of participants at the highest dose lost at least 20 percent of their body weight. Crucially, the weight loss curve had not yet plateaued at 48 weeks, suggesting continued treatment may produce even greater results.

Liver Fat Reduction

One of the most clinically significant secondary findings from retatrutide trials has been its effect on hepatic fat content. In a Phase 2 trial in adults with type 2 diabetes and obesity, retatrutide reduced liver fat by up to 82 percent at the 12 mg dose, with the majority of participants achieving normalization of liver fat content (3). Non-alcoholic fatty liver disease (now more accurately called MASLD) affects an estimated 25 percent of adults globally and is a leading driver of cirrhosis and liver transplant need. Retatrutide’s liver fat reduction data is among the most impressive ever reported for a pharmaceutical intervention.

Head-to-Head Context

For comparison:

Medication	Trial	Duration	Average Weight Loss
Semaglutide 2.4 mg	STEP 1	68 weeks	14.9 percent
Tirzepatide 15 mg	SURMOUNT-1	72 weeks	22.5 percent
Retatrutide 12 mg	Phase 2	48 weeks	24.2 percent

Retatrutide achieved greater average weight loss than tirzepatide in a shorter trial duration. If future Phase 3 data confirms these results at 72 or 96 weeks, the ceiling for pharmaceutical weight loss may be substantially higher than previously assumed.

Retatrutide vs Tirzepatide: Why Patients Are Switching

Patients who have already been through a GLP-1 or dual-agonist protocol ask the same question: is it worth switching to retatrutide? The honest answer is: it depends.

The case for switching: Many patients achieve impressive initial results on tirzepatide but eventually plateau — their weight loss slows or stalls despite continued treatment. The plateau reflects metabolic adaptation: as you lose weight, your basal metabolic rate decreases, and the gap between calories consumed and calories expended narrows until weight stabilizes. Retatrutide’s glucagon pathway directly counteracts this adaptation by raising metabolic rate rather than just suppressing appetite. For plateaued patients, the triple-agonist mechanism can produce additional weight loss that dual-agonists cannot.

The case for staying: If you are achieving strong results on tirzepatide and tolerating it well, switching to retatrutide for a marginal improvement may not be worth the transition. Clinical experience with tirzepatide is substantially longer, and its side effect profile is well-characterized. Retatrutide may have slightly more pronounced GI effects initially due to the triple-agonist mechanism.

The stepping-stone approach: For most patients, we think about medical weight loss as a progression. If you are new to GLP-1 therapy, tirzepatide or semaglutide is usually the right starting point. If you achieve your goal on one of these, continue. If you plateau below your target, retatrutide is the logical next step.

Who Is Retatrutide Right For?

Based on current clinical data and our experience, retatrutide is most appropriate for:

• Patients who have plateaued on semaglutide or tirzepatide. The additional glucagon pathway addresses metabolic adaptation that dual-agonists cannot.
• Patients with significant weight to lose — typically 50 pounds or more. The larger your weight loss target, the more meaningful the incremental advantage retatrutide provides.
• Patients with fatty liver disease (MASLD/NAFLD) or metabolic syndrome. The hepatic fat reduction data is substantially stronger than for semaglutide or tirzepatide.
• Patients with insulin resistance or prediabetes who would benefit from comprehensive metabolic effects beyond weight loss alone.

Retatrutide is typically not the right medication for:

• First-time GLP-1 users — we generally start with tirzepatide.
• Patients with severe gastrointestinal disorders or active pancreatitis history.
• Patients with medullary thyroid carcinoma or MEN2 syndrome (a class warning for all GLP-1 agonists).
• Pregnant or breastfeeding women.

Every protocol at Rewind begins with comprehensive lab work and a detailed clinical assessment to ensure the right medication is matched to the right patient.

Side Effects and What to Expect

Retatrutide’s side effect profile closely resembles tirzepatide’s, with gastrointestinal effects most common during dose escalation:

• Nausea: Reported by 16 to 43 percent of participants in trials, dose-dependent, most common during dose escalation
• Diarrhea: Reported by 15 to 25 percent
• Vomiting: Reported by 8 to 15 percent
• Constipation: Reported by 6 to 12 percent
• Decreased appetite: Nearly universal (and considered a therapeutic effect)

Most side effects are transient and improve within two to four weeks at each dose level. Our standard approach minimizes them through gradual titration, adequate hydration, adequate protein intake (0.7 to 1.0 grams per pound of ideal body weight), and patient education about what to expect and when to call us. Rapid escalation is the single most common reason patients struggle with side effects — we do not rush the titration schedule.

Rare but serious risks include pancreatitis, gallbladder disease associated with rapid weight loss, and potential thyroid concerns (a class warning based on rodent studies). These are uncommon but are screened for during initial evaluation and monitored throughout treatment.

Why Most Miami Clinics Don’t Offer Retatrutide

Retatrutide is not widely available yet for several reasons:

1. It is still investigational. Many clinics will not prescribe a medication that has not received FDA approval, even through compounding pathways where it is legally available.
2. It requires established compounding pharmacy relationships. Access to pharmaceutical-grade compounded retatrutide requires trusted, credentialed compounding partners.
3. Triple-agonist protocols require provider expertise. Dosing, titration, and monitoring differ from single or dual-agonist therapy. Most clinics are still catching up to tirzepatide.
4. Monitoring requires comprehensive labs. At Rewind, we monitor hepatic function, lipid panel, metabolic markers, and body composition throughout treatment — not just weight.

Rewind has been offering retatrutide since it became available through compounding. Our approach is lab-based, supervised, and personalized. We are not a prescribe-and-forget clinic.

Getting Started at Rewind

Every retatrutide protocol at Rewind begins with three things:

1. Comprehensive metabolic panel and body composition analysis. We establish your baseline — hepatic function, lipids, thyroid, sex hormones, fasting insulin, HOMA-IR, HbA1c, inflammatory markers. Body composition (lean mass, fat mass, visceral fat) is measured so we can track what is actually changing, not just what the scale says.
2. Clinical assessment and history review. Prior weight loss attempts, prior GLP-1 use, medications, medical history, goals. This determines whether retatrutide is the right choice or whether tirzepatide or another approach makes more sense.
3. Personalized protocol and titration plan. Your starting dose, escalation schedule, and monitoring cadence are individualized. Protein targets and lifestyle guidance are built around you, not a generic template.

Interested in seeing whether you are a candidate? Take our 2-minute quiz to get a personalized recommendation, or contact us directly to schedule a consultation. If you want to understand our overall approach to weight loss, our medical weight loss page covers every option we offer — from semaglutide and tirzepatide to retatrutide, tesofensine, and peptide-based support.

Related Articles

• How Does Retatrutide Work? The Triple-Action Peptide Explained
• Retatrutide vs Tirzepatide: What Patients Need to Know
• Retatrutide vs Semaglutide: Comparing Weight Loss Results

References

1. Nair KS. Hyperglucagonemia increases resting metabolic rate in man during insulin deficiency. J Clin Endocrinol Metab. 1987;64(5):896-901.
2. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N Engl J Med. 2023;389(6):514-526.
3. Rosenstock J, Frias JP, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. Lancet. 2023;402(10401):529-544.

---

Ready to see if retatrutide is right for you? Rewind Anti-Aging of Miami offers retatrutide therapy with comprehensive lab-based monitoring and personalized titration. Take our quiz or schedule a consultation →

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Retatrutide is an investigational medication not yet approved by the FDA. Weight loss medications should only be used under the supervision of a qualified healthcare provider. Individual results vary.